Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) will present at the Leerink Partners Global Healthcare Conference in Miami on Tuesday, March 10, 2025 at 1:00 p.m. ET.
The presentation will be webcast and accessible via the company’s Events and Presentations investor web page, with a replay available for at least 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – FULC
On the day this news was published, FULC gained 0.77%, reflecting a mild positive market reaction. Argus tracked a peak move of +4.9% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $568M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
FULC fell 6.8% while key biotech peers like LXRX (+9.86%), LRMR (+4.06%), PRTC (+2.31%), SLDB (+2.82%) and AUTL (+0.6%) traded higher. Peer momentum data flags only LRMR in an "up" scan and sector-wide momentum is marked false, pointing to a stock-specific move rather than a broad biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Earnings & trial data | Positive | -21.2% | Reported positive Phase 1b PIONEER data and 2025 financial results. |
| Feb 24 | Clinical results | Positive | -21.2% | Detailed positive 12-week results from 20 mg PIONEER cohort in sickle cell. |
| Feb 17 | Data presentation notice | Neutral | +0.3% | Announced upcoming webcast of 12-week PIONEER 20 mg data presentation. |
| Feb 06 | Inducement option grant | Neutral | +5.0% | Granted 70,000 inducement options at $10.72 under stock incentive plan. |
| Jan 09 | Inducement option grants | Neutral | -3.5% | Granted 30,400 options to new employees under Nasdaq Rule 5635(c)(4). |
Positive clinical and earnings updates on Feb 24, 2026 coincided with a 21.21% selloff, suggesting a pattern where ostensibly good news has not translated into positive price action.
Over recent months, Fulcrum’s trajectory has centered on pociredir in sickle cell disease and ongoing equity-based compensation. On Feb 24, 2026, the company reported positive Phase 1b PIONEER data and 2025 financials, yet shares dropped 21.21%. Earlier, a data-presentation notice on Feb 17, 2026 had little impact, while inducement option grants in early February and January produced modest, mixed reactions. Today’s conference-participation news fits into a cadence of regular investor-focused communications.
Market Pulse Summary
This announcement highlights Fulcrum’s participation in a major healthcare investor conference, with a webcast on March 10, 2025 at 1:00 p.m. ET and a replay available for at least 30 days. In recent months, the company has reported positive Phase 1b data for pociredir and detailed significant 2025 net losses and cash levels in SEC filings. Observers may watch for new clinical, financial, or strategic details shared alongside the conference appearance.
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will present at the Leerink Partners Global Healthcare Conference in Miami, FL on Tuesday, March 10, 2025 at 1:00 p.m. ET.
The webcast of the presentation will be accessible HERE or by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcast will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentation.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of HbF for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
When will Fulcrum Therapeutics (FULC) present at the Leerink Partners Global Healthcare Conference?
How can investors watch the Fulcrum Therapeutics (FULC) presentation on March 10, 2025?
Will Fulcrum Therapeutics (FULC) provide a replay of the March 10, 2025 conference presentation?
Will Fulcrum Therapeutics (FULC) publish presentation slides from the March 10, 2025 session?
What topics will Fulcrum Therapeutics (FULC) management likely cover at the March 10, 2025 Leerink conference?
Where can U.S. investors find the webcast link and replay for Fulcrum Therapeutics (FULC) presentation?
